{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '4.', \"INVESTIGATOR'S SIGNATURE\", 'An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs', 'Chemotherapy in Subjects with Previously Treated Locally Advanced or', 'Metastatic Urothelial Cancer (EV-301)', 'ISN/Protocol 7465-CL-0301', 'Version 4.0 Incorporating Substantial Amendment 3', '14 Sep 2020', 'I have read all pages of this clinical study protocol for which Astellas is the sponsor. I agree to', 'conduct the study as outlined in the protocol and to comply with all the terms and conditions set', 'out therein. I confirm that I will conduct the study in accordance with International Council for', 'Harmonisation (ICH) Good Clinical Practice (GCP) guidelines and applicable local regulations. I', 'will also ensure that subinvestigator(s) and other relevant members of my staff have access to', 'copies of this protocol and the ICH GCP guidelines to enable them to work in accordance with the', 'provisions of these documents.', 'Principal Investigator:', 'Signature:', 'Date (DD MMM YYYY)', 'Printed Name:', '<Insert name and qualification of the Investigator>', 'Address:', '14 Sep 2020', 'Astellas', 'Page 11 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'II.', \"CONTACT DETAILS OF KEY SPONSOR'S PERSONNEL\", '24h-Contact for Serious', 'Please fax or email the SAE Worksheet to:', 'Adverse Events (SAEs)', 'Astellas Pharma Global Development, Inc.', 'Global Pharmacovigilance', 'See [Section 5.6.5', 'Reporting', 'North America Fax: 1-888-396-3750', 'of Serious Adverse Events] for', 'North America Alternate Fax: 1-847-317-1241', 'SAE Fax Number and Email', 'International Fax: +44-800-471-5263', 'Email: safety-us@astellas.com', 'For Japan:', 'PAREXEL International', 'Clinical Development', 'Fax number +81-(0)3-6888-1654', 'Astellas Pharma Inc. - Japan', 'JP Clinical Development', 'Fax number +81-(0)3-3243-5737', 'Parexel Medical Monitor:', 'PPD', 'PAREXEL International', 'PPD', 'Astellas Medical Expert:', 'PPD', 'Medical Science Oncology,', 'Astellas Pharma Global Development, Inc.', '1 Astellas Way', 'Northbrook, IL 60062', 'PPD', 'Clinical Research Contacts:', 'PPD', 'Clinical Science', 'Astellas Pharma Global Development, Inc.', '1 Astellas Way', 'Northbrook, IL 60062', 'PPD', '14 Sep 2020', 'Astellas', 'Page 12 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'III.', 'LIST OF ABBREVIATIONS AND DEFINITION OF KEY TERMS', 'List of Abbreviations', 'Abbreviations', 'Description of abbreviations', 'ADC', 'Antibody drug conjugate', 'AE', 'adverse event', 'Alb', 'albumin', 'ALP', 'alkaline phosphatase', 'ALT', 'alanine aminotransferase', 'ANC', 'absolute neutrophil count', 'APEBV', 'Astellas Pharma Europe B.V.', 'APGD', 'Astellas Pharma Global Development', 'AST', 'aspartate aminotransferase', 'AT', 'aminotransferases', 'ATA', 'antitherapeutic antibodies', 'AUST', 'Astellas US Technologies', 'BLOQ', 'below the lower limit of quantification', 'BUN', 'blood urea nitrogen', 'CA', 'competent authority', 'cfDNA', 'circulating free deoxyribonucleic acid', 'CFR', 'Code of Federal Regulations', 'CHO', 'Chinese Hamster Ovary', 'CIOMS', 'council for international organizations of medical sciences', 'CNS', 'central nervous system', 'CPI', 'checkpoint inhibitor', 'CR', 'complete response', 'CrCl', 'creatinine clearance', 'CRF', 'case report form', 'CRO', 'contract research organization', 'CT', 'computed tomography', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'CV', 'coefficient of variation', 'COE', 'crossover extension', 'CYP3A4', 'cytochrome P450 3A4', 'DCR', 'disease control rate', 'DILI', 'drug-induced liver injury', 'DLT', 'dose-limiting toxicity', 'DOR', 'duration of response', 'ECG', 'electrocardiogram', 'ECOG PS', 'Eastern Cooperative Oncology Group Performance Status', 'eCRF', 'electronic case report form', 'EDC', 'electronic data capture', 'EEA', 'European Economic Area', '14 Sep 2020', 'Astellas', 'Page 13 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}